Immuno Oncology Partnerships Nanolive’s LIVE T Cell Assay and AI-powered immune profiling enable potential customers in immuno-oncology and cell therapy to profile T cell activity without labeling. Target pharma, biotech and CROs looking to accelerate immune-monitoring, biomarker discovery, and therapeutic development with live-cell imaging insights.

Imaging Growth Markets The company focuses on 3D live-cell imaging for drug discovery and cell therapy, presenting a compelling opportunity to approach biotech startups and academic groups needing dynamic cellular data to de-risk projects and accelerate lead optimization.

Mitochondrial Dynamics Offering The AI-based tool for mitochondrial dynamics real-time monitoring opens a cross selling path into toxicology and metabolic research; pitch to researchers studying mitochondrial dysfunction, apoptosis, and drug safety who need quantitative live data.

Partnerships and Expansion With a small team and European HQ, Nanolive can be a favorable partner for co-development, distributor agreements, or technology licensing with CROs and large instrument firms looking to add 3D imaging and AI analytics to their portfolios.

Analytics Software Bundling Bundle hardware with analytics software as a service, integrating with existing data ecosystems and standard tools. Emphasize AI capabilities and Nanolive's oncology and toxicology publications to drive enterprise-grade licenses for R&D centers.